GWS
AKRO

Glassman Wealth Services’s Akero Therapeutics AKRO Stock Holding History

Glassman Wealth Services’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16
Closed -$374 – 261
2023
Q4 		$374 Buy
+16
New +$316 ﹤0.01% 1772

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Glassman Wealth Services's AKRO Position: Q1 2024 in Review

Glassman Wealth Services sold out of Akero Therapeutics (AKRO) in Q1 2024, closing a stake of 16 shares — an estimated $374 sold.

Glassman Wealth Services first reported a position in AKRO in Q4 2023 and held it in 1 quarter. The position peaked at $374 in Q4 2023. 173 funds tracked by Wall St. Rank hold AKRO as of Q1 2024.

  • Glassman Wealth Services reported no remaining Akero Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Glassman Wealth Services sold 16 Akero Therapeutics shares in Q1 2024, an estimated $374.
  • Glassman Wealth Services first reported a position in Akero Therapeutics in Q4 2023 and held it in 1 quarter.
  • Glassman Wealth Services's Akero Therapeutics position peaked at $374 in Q4 2023.
  • 173 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.